About Oryzon Genomics S.A.

Company Description

Founded in 2000 in Barcelona, Spain, Oryzon is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. Oryzon has one of the strongest portfolios in the field. Oryzon’s LSD1 program has rendered two compounds Vafidemstat and Iadademstat in Phase II clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon has offices in Spain and the United States.

Year founded

2000

Served area

Europe + North America

Headcount

43

Headquarters

Carrera de San Jeronimo 15, 28014 Madrid – Spain

Publications

Shareholder information

Shares outstanding

53,960,000

IPO

Dec. 14, 2015

Stock exchange(s)

Bolsa de Madrid

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.